Abstract
The hyperlipidaemias are a common and heterogeneous group of metabolic disorders which affect more than 10% of the population of Western industrialized countries [1–3]. Although hypertension and diabetes mellitus are well established as predisposing factors for the development of atherosclerotic disease [4, 5] the role of dietary fat and altered lipoprotein metabolism is not so well understood [6–8]. Epidemiological studies have demonstrated that increased levels of plasma cholesterol may be associated with premature coronary heart disease [2, 3] and the United States Lipid Research Clinics trial [9] has given clear evidence that reducing high cholesterol levels in men will lower the incidence of coronary heart disease (CHD), and additionally will significantly reduce deaths, myocardial infarcts, angina and the need for coronary artery bypass surgery. These results confirm previous similar reports [10–12].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Carlson, L.A. and Linstedt, S. (1969) The Stockholm Prospective Study. The initial values for plasma lipids. Acta Med. Scand., Suppl., 493.
Kannel, W.B., Castelli, W.P., Gordon, T. et al. (1971) Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Intern. Med., 74, 1.
Fuller, J.H., Pinney, S., Jarrett, R.J. et al. (1978) Plasma lipids in a London population and their relation to other risk factors for coronary heart disease. Br. Heart J., 40, 170.
Marks, H.H., Krall, L.P. and White, P. (1971) Epidemiology and detection of diabetes mellitus. In Joslin’s Diabetes Mellitus (ed. Marble, White, Bradley and Krall), Lea and Febiger, Philadelphia.
Walker, W.J. (1976) Success story: the Program against major cardiovascular risk factors. Geriatrics, 31, 97.
Walker, A.R.P. (1978) Diet and coronary heart disease. S. Afr. Med. J., 53, 587.
Mann, G.V. et al. (1978) Diet-heart era: premature obituary? N. Engl. J. Med., 298, 106–8.
Ahrens, E.H. (1979) Dietary fats and coronary heart disease: unfinished business. Lancet, 2, 1345.
The Lipid Research Clinics coronary primary prevention trial results (1984) J. Am. Med. Assoc., 251, 351.
Dayton, S., Pearce, M.L., Hashimoto, S. et al. (1969) A controlled trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation, 40, (Suppl. 2), 1.
Hjermann, I., Byre, K.V., Holme, I. et al. (1981) Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo study group of a randomised trial in healthy men. Lancet, 2, 1303.
WHO Clofibrate Trial Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40, 1069.
Carlson, L.A. and Bottiger, L.E. (1972) Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol: Stockholm Prospective Study. Lancet, 1, 865.
Carlson, L.A., Bottiger, L.E. and Ahfeldt, P.E. (1979) Risk factors for myocardial infarction in the Stockholm Prospective Study: A 14 year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med. Scand., 206, 351.
Hulley, S.B., Rosenman, R.H., Bawol, R.D. et al. (1980) Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease. N. Engl. J. Med., 382, 1383.
Chivers, A.G., Lea Thomas, M. and Browse, N.L. (1974) The Progression of arteriosclerosis. A radiological study. Circulation, 50, 402.
Gensini, G.G., Esente, P. and Kelly, A. (1974) Natural history of coronary disease in patients with and without coronary bypass graft surgery. Circulation, 50, 98.
Duffield, R.G.M., Lewis, B., Miller, N.E. et al. (1983) Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. Lancet, 2, 639.
Galton, D.J., Stocks, J. and Dodson, P.M. (1982) Lipoproteins - their role in enzyme regulation. In Clinical Biochemistry Review, Vol. 3. (ed. D.M. Golberg) Wiley, New York.
Beaumont, J.L., Carlson, L.A., C000per, G.R. et al. (1970) Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull. Wld. Hlth, Org., 43, 891.
Fredrickson, D.S., Goldstein, J.L. and Brown, M.S. (1983) in The Metabolic Basis of Inherited Disease, 5th edn, (eds J.B. Stanbury, J.B. Wyngaarden, & D.S. Fredrickson). McGraw-Hill, New York.
Lewis, B., Chait, A., Wootton, I.D.P. et al. (1974) Frequency of risk factors in a healthy British population. Lancet, i, 141.
Tall, A.R. and Small, D.M. (1978) Current concepts. Plasma high density lipoproteins. N. Engl. J. Med., 299, 1232.
Gordon, T. (1980) HDL and coronary heart disease (letter). Lancet, 2, 1139.
Durstine, J.L., Miller, W., Farrell, W.M. and Ivy, J.L. (1983) Increases in HDL-cholesterol and the HDL/LDL cholesterol ratio during prolonged endurance exercise. Metabolism, 32, 10.
Morris, J.N., Everitt, M.G. and Pollard, R. (1980) Vigorous exercise in leisure-time: Protection against coronary heart disease. Lancet, 2, 1207.
Schlierf, G., Chwat, M., Feverborn, et al. (1980) Bezafibrate and clofibrate in hyperlipidaemia. Atherosclerosis, 36, 323.
Coronary Project Group (1975) Clofibrate and niacin in coronary heart disease. J. Am. Med. Assoc., 231, 360.
Committee of Principal Investigators (1980) WHO cooperative trial on the prevention of ischaemic heart disease using clofibrate to lower serum cholesterol. Mortality follow-up. Lancet, 11, 379.
Keen, H., Lewis, B., Miller, N.E. et al. (1980) Clofibrate and hyperlipidaemia. Lancet, 2, 1241.
Lelorier, J., Dubrenil-Quidoz, S., Lussier-Cacan, S. et al. (1977) Diet and probucol in lowering cholesterol concentrations. Arch. Intern. Med., 137, 1429.
Shepherd, J., Packard, C.J., Patsch, J.R. et al. (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and apoprotein A metabolism. J. Clin. Invest., 63, 858.
Kane, J.P., Malloy, M.J., Tun, P. et al. (1981) Normalization of low-densitylipoprotein levels in heterozygous familial hypercholesterolaemia with a combined drug regimen. N. Engl. J. Med., 304, 251.
Witztum, J.L., Schonfield, D. and Weidman, S.W. (1976) The effect of colestipol on the metabolism of very low density lipoproteins in man. J. Lab. Clin. Med., 88, 108.
Hashim, S.A. and Italie, T.B. (1965) Cholestyramine resin therapy for hypercholesterolaemia. J. Am. Med. Assoc., 192, 289.
Levy, R.L., Fredrickson, D.S., Kwiterovich, P.O. et al. (1969) Normalisation of lipids in familial hypercholesterolaemia. Circulation, 40, (Suppl.3), 15.
Glueck, C.J., Ford, S. Scheel, D, et al. (1972) Colestipol and cholestyramine resin. J. Am. Med. Assoc., 222, 676.
Buchwald, H., Moore, R.B. and Varco, R.L. (1981) in Atherosclerosis V (eds A.M. Gotto et al.), Springer-Verlag, Berlin, pp. 462–5.
Chalstrey, L.J., Winder, A.F. and Galton, D.J. (1982) Partial ileal bypass in the treatment of familial hypercholesterolaemia. J. Roy. Soc Med., 75, 851–6.
Thompson, G.R., Lowenthal, R. and Myant, N.B. (1975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet, 2, 1208.
Brook, G., Winterstein, G. and Aviram, M. (1983) Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia. Clin. Sci., 64, 637.
Lerne, P., Foss, P.O., Helgeland, A. et al. (1980) Effect of propranolol and Prazosin on blood lipids. The Oslo Study. Lancet, 2, 4.
Grimm, R.H., Leon, A.S., Hunninghake, D.B. et al. (1965) Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. A double-blind controlled trial. Ann. Intern. Med., 94, 7.
Samuel, P. (1980) Drug treatment of hyperlipidaemia. Am. Heart J., 100, 573.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Jowett, N.I., Galton, D.J. (1987). The management of the hyperlipidaemias. In: Hamer, J. (eds) Drugs for Heart Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-3294-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4899-3294-5_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-412-26540-2
Online ISBN: 978-1-4899-3294-5
eBook Packages: Springer Book Archive